Brahms GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.4M
Doctors Paid
14
Transactions
512
2024 Total
$101,820
Payment Breakdown by Category
Research$5.6M (75.5%)
Royalty/License$1.7M (23.3%)
Travel$50,025 (0.7%)
Consulting$32,166 (0.4%)
Food & Beverage$1,198 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.6M | 339 | 75.5% |
| Royalty or License | $1.7M | 134 | 23.3% |
| Travel and Lodging | $50,025 | 19 | 0.7% |
| Consulting Fee | $32,166 | 4 | 0.4% |
| Honoraria | $8,902 | 6 | 0.1% |
| Food and Beverage | $1,198 | 10 | 0.0% |
Payments by Type
Research
$5.6M
339 transactions
General
$1.8M
173 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Chromogranin A as Surveillance biomarker in Patients with cARcinoids - the CASPAR study | $1.4M | 0 | 194 |
| PROcalcitonin impact on antibiotic reduction, adverSe events and AVoidable healthcarE costs (ProSAVE) | $1.3M | 0 | 8 |
| Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnangy - PRAECIS | $687,971 | 0 | 20 |
| First Trimester Risk Assessment For Preeclampsia Study FITRAPS | $595,553 | 0 | 13 |
| Identification and validation of a cut-off for the ratio of suluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnancy - PRAECIS | $500,000 | 0 | 5 |
| Chromogranin A as surveillance biomarker in patients with cARcinoids - The CASPAR Pilot study | $259,054 | 0 | 12 |
| PROcalcitonin impact on antibiotic reduction, adverSe events and AVoidable healthcarE costs (ProSAVE): A RCT | $200,000 | 0 | 3 |
| ProACT Microbiome | $117,609 | 0 | 3 |
| First Trimester Risk Assessment for Preeclampsia study (FITRAPS) | $102,615 | 0 | 19 |
| Procalcitonin Decres over 72 hours and outcom in aptients with severe sepsis or septic shock (MOSES) | $89,424 | 0 | 7 |
| First Trimester Risk Assessment For Preeclampsia Study (FITRAPS) | $75,000 | 0 | 1 |
| CASPAR-study Reference Range study for chromogranin A and copeptin proAVP | $57,164 | 0 | 22 |
| Identification and validation of a cut-off for ration soluble Fms-like Tyrosine Kinase-1 to placental growth factor to stratify rist in pregnat women with hypertensive disorders | $57,057 | 0 | 1 |
| PCT Protocol for JHBMC: A Stewardship Project | $56,375 | 0 | 11 |
| COVID-19 Study | $50,813 | 0 | 2 |
| Retrospective pilot derivation of Chromogranin A threshold to aid in the assessment of progressive disease | $44,002 | 0 | 1 |
| various validation studies | $37,845 | 0 | 7 |
| Angiogenic factors and postpartum hypertension | $12,000 | 0 | 2 |
| Novel Biomarker identification of severe sepsis and septic shock in the early pre-sepsis phase | $8,059 | 0 | 2 |
| Identification and Validation of a Cut-off for the Ratio of Soluble Fms-like Tyrosine Kinase-1 to Placental Growth Factor (sFlt-1/PlGF) to Stratify Risk in Pregnant Women with Hypertensive Disorders of Pregnangy - PRAECIS and First Trimester Risk Assessment for Preeclampsia study (FITRAPS) | $6,000 | 0 | 1 |
| Evaluation of Hemodynamic Biomarkers in Patients with Diabetes Mellitus (SAVOR - TIMI 53) | $6,000 | 0 | 1 |
| Copeptin as a predictor of dysnatremia in the pediatric population following pituitary surgery | $4,001 | 0 | 3 |
| Longitudinal changes in copeptin and risk of cardio-renal disease in adults with type 1 diabetes | $1,033 | 0 | 1 |
Payments by Medical Specialty
| Specialty | Total Paid | Doctors | Avg/Doctor |
|---|---|---|---|
| Pediatrics | $26,135 | 2 | $13,068 |
| Critical Care Medicine | $10,525 | 1 | $10,525 |
| Pediatric Critical Care Medicine | $8,124 | 1 | $8,124 |
| Nephrology | $7,230 | 1 | $7,230 |
| Internal Medicine | $6,782 | 2 | $3,391 |
| Emergency Medicine | $3,547 | 1 | $3,547 |
| Infectious Disease | $1,925 | 1 | $1,925 |
| Cardiovascular Disease | $1,846 | 1 | $1,846 |
| Maternal & Fetal Medicine | $1,109 | 2 | $554.73 |
| Medical Oncology | $67.50 | 2 | $33.75 |
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Robert Pantell, M.d, M.D | Pediatrics | San Francisco, CA | $15,365 | $0 |
| Scott Weiss, M.d, M.D | Pediatrics | Philadelphia, PA | $10,770 | $0 |
| Dr. Eric Gluck, M.d, M.D | Critical Care Medicine | Chicago, IL | $10,525 | $0 |
| Dr. Adrienne Randolph, Md, Msc, MD, MSC | Pediatric Critical Care Medicine | Boston, MA | $8,124 | $0 |
| Dr. Subbian Karumanchi, M.d, M.D | Nephrology | Boston, MA | $7,230 | $0 |
| Dr. Ravi Thadhani, Md, Mph, MD, MPH | Internal Medicine | Boston, MA | $6,748 | $0 |
| Sean Neath, Md, MD | Emergency Medicine | Manchester, NH | $3,547 | $0 |
| Dr. Jennifer Townsend, M.d, M.D | Infectious Disease | Baltimore, MD | $1,925 | $0 |
| Dr. Alan Maisel, Md, MD | Cardiovascular Disease | San Diego, CA | $1,846 | $0 |
| Sarosh Rana | Maternal & Fetal Medicine | Chicago, IL | $726.46 | $0 |
| Dr. Kim Boggess, Md, MD | Maternal & Fetal Medicine | Chapel Hill, NC | $383.00 | $0 |
| Dr. Thorvardur Halfdanarson, M.d, M.D | Internal Medicine | Rochester, MN | $33.75 | $0 |
| Dr. Pamela Kunz, M.d, M.D | Medical Oncology | New Haven, CT | $33.75 | $0 |
| Daniel Halperin, Md, MD | Medical Oncology | Houston, TX | $33.75 | $0 |
Ad
Top Products
- PlGF plus $889,734
- PIGF plus $855,487
Associated Products (25)
- PlGF plus $889,734
- PIGF plus $855,487
- BRAHMS KPRYTOR CgA II $853,070
- BRAHMS KRYPTOR sFlt-1 $623,871
- BRAHMS KRYPTOR sFlt-1 and PlGF $500,000
- BRAHMS KYPTOR PCT $500,000
- BRAHMS KRYPTOR sFlt-1 and PlGF plus $465,000
- BRAHMS KRYPTOR Procalcitonin $450,813
- PCT $404,382
- BRAHMS PCT KRYPTOR $381,816
- Chromogranin A $378,788
- BRAHMS KRYPTOR CgA II $322,979
- BRAHMS PCT KYPTOR $250,000
- BRAHMS sFlt-1 and PlGF plus KRYPTOR $150,000
- BRAHMS KRYPTOR compact PLUS (instrument) $123,500
- BRAHMS PlGF plus KRYPTOR $80,000
- BRAHMS sFlt-1 KRYPTOR $75,000
- sFlt-1 $58,039
- BRAHMS KPRYTOR CgA II and BRAHMS KRYPTOR compact PLUS consumables $50,452
- BRAHMS CgA II KRYPTOR $49,674
- Kryptor instrument $34,500
- BRAHMS Chromogranin A KRYPTOR $34,481
- BRAHMS PCT $34,259
- Chromogranin-A II $20,100
- BRAHMS KRYPTOR sFlt-1 kits and consumables $11,851
Payment Categories
- Food & Beverage $1,198
- Consulting $32,166
- Travel & Lodging $50,025
- Research $5.6M
- Royalties $1.7M
About Brahms GmbH
Brahms GmbH has made $7.4M in payments to 14 healthcare providers, recorded across 512 transactions in the CMS Open Payments database. In 2024, the company paid $101,820. The top product by payment volume is PlGF plus ($889,734).
Payments were distributed across 10 medical specialties. The top specialty by payment amount is Pediatrics ($26,135 to 2 doctors).
Payment categories include: Food & Beverage ($1,198), Consulting ($32,166), Research ($5.6M), Travel & Lodging ($50,025), Royalties ($1.7M).
Brahms GmbH is associated with 25 products in the CMS Open Payments database, including PlGF plus, PIGF plus, and BRAHMS KPRYTOR CgA II.